Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Net Cash Flow (2016 - 2025)

Ultragenyx Pharmaceutical (RARE) has disclosed Net Cash Flow for 10 consecutive years, with $222.1 million as the latest value for Q4 2025.

  • Quarterly Net Cash Flow rose 749.94% to $222.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $248.0 million through Dec 2025, up 851.52% year-over-year, with the annual reading at $248.0 million for FY2025, 851.52% up from the prior year.
  • Net Cash Flow for Q4 2025 was $222.1 million at Ultragenyx Pharmaceutical, up from $25.8 million in the prior quarter.
  • The five-year high for Net Cash Flow was $368.5 million in Q2 2024, with the low at -$331.3 million in Q3 2024.
  • Average Net Cash Flow over 5 years is -$14.5 million, with a median of -$10.3 million recorded in 2022.
  • Peak annual rise in Net Cash Flow hit 2164.18% in 2024, while the deepest fall reached 1068.89% in 2024.
  • Over 5 years, Net Cash Flow stood at $100.4 million in 2021, then plummeted by 358.92% to -$260.1 million in 2022, then skyrocketed by 153.59% to $139.4 million in 2023, then plummeted by 81.25% to $26.1 million in 2024, then skyrocketed by 749.94% to $222.1 million in 2025.
  • According to Business Quant data, Net Cash Flow over the past three periods came in at $222.1 million, $25.8 million, and $46.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.